Press Release | Newsroom | Medtronic | Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting

DUBLIN - June 7, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans. Among the presentations are late breaking pivotal trial  results of the Hybrid Closed Loop system, pivotal trial results for the company's fourth generation sensor and further study of the company's SmartGuard(TM) technology. Hybrid Closed Loop system is approved for investigational use only in the U.S., and many devices being presented at ADA are also investigational use only.

"At ADA 2016, we have a number of important data presentations about our marketed products and key products in our pipeline, most notably our Hybrid Closed Loop system and next generation sensor," said Francine R. Kaufman, M.D., chief medical officer and vice president of global, clinical and medical affairs for Medtronic Diabetes. "We are proud to be the first company to present results of a pivotal trial of a closed loop system, which is designed to automatically control glucose levels 24 hours a day with less input from patients, as we continue toward our goal of helping people with diabetes enjoy greater freedom and better health."

"The ability for people with diabetes to achieve better glucose control and live longer, healthier lives has significantly improved with insulin pumps and continuous glucose monitoring systems. However, patients must still make frequent decisions each day while using today's systems," said Richard M. Bergenstal, M.D., of the International Diabetes Center in Minneapolis. "Simplifying this self-management and adding a little peace of mind with this more automated Hybrid Closed Loop system would impact these patients' lives in a very meaningful way."

Scientific Presentations
Closing the Loop

Sensing
The conference will showcase advancements of Medtronic continuous glucose monitoring (CGM) technology with intelligent diagnostics and sensor redundancy, resulting in market-leading accuracy, usability and reliability for both stand-alone and closed-loop CGM systems.

Health Economics

Type 2 Diabetes

Company Presentations
Medtronic will host a series of presentations at Booth #301 from Saturday through Monday, where the audience will get the opportunity to hear from experts regarding the application of Medtronic technologies in their practice.

  • Transforming Data into Actions with Personalized Diabetes Insights: Saturday, June 11 at 10:30 a.m.; Sunday, June 12 at 3 p.m.; Monday, June 13 at 1 p.m.
  • Advances in the Use of iPro2 in Type 2 Diabetes:  Saturday, June 11 at 1 p.m. and Sunday, June 12 at 1:30 p.m.
  • Improving Outcomes Through Automation with SmartGuard Technology: Saturday, June 11 at 3 p.m.; Sunday, June 12 at 10:30 a.m.; Monday, June 13 at 10:30 a.m.

Analyst and Investor Briefing
Medtronic will host a webcast to provide an update on its Diabetes Group during the conference on Sunday, June 12 from 2 p.m. to approximately 4 p.m. CDT. The webcast will feature remarks from Medtronic management, including comments on Medtronic's clinical data, product pipelines, and market outlooks. The live audio webcast can be accessed at http://investorrelations.medtronic.com on June 12. Within 24 hours of the webcast, a replay will be available by clicking on the Investor Events link at http://investorrelations.medtronic.com. This event is not part of the official ADA Scientific Sessions.

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

 

Contacts:
Pamela Reese
Public Relations
+1-818-576-3398

Ryan Weispfenning
Investor Relations
+1-763-505-4626


HUG#2018380
X